PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS

ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple st...

Full description

Saved in:
Bibliographic Details
Published in:Arquivos de gastroenterologia Vol. 58; no. 2; pp. 139 - 144
Main Authors: SMIDERLE, Carla Alessandra, CORAL, Gabriela Perdomo, DE CARLI, Luiz Alberto, MATTOS, Angelo Alves de, MATTOS, Angelo Zambam de, TOVO, Cristiane Valle
Format: Journal Article
Language:English
Published: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE 01-06-2021
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple steatosis, which has a benign course, to steatohepatitis, which may progress to cirrhosis and its complications. The rising of noninvasive methods for diagnosing and staging non-alcoholic steatohepatitis (NASH) and fibrosis decreases the need of liver biopsy, as well as the costs and the occurrence of complications related to it. OBJECTIVE: To analyze the performance of the triglyceride-glucose index to evaluate steatosis, NASH and liver fibrosis in obese patients with NAFLD. METHODS: This is a retrospective cross-sectional study. Every medical record of patients who were candidates for bariatric surgery at a leading hospital in Southern Brazil were analyzed. The triglyceride-glucose index (TyG Index), a method composed only of two simple laboratory tests (serum triglycerides and fasting glucose levels), was performed prior to surgery. The TyG Index performance regarding the anatomopathological findings was evaluated, and the AUROC curve was calculated to evaluate the best cut-off point for diagnosing steatosis, non-alcoholic steatohepatitis and liver fibrosis grade. Also, the NAFLD fibrosis Score (NFS) was evaluated. RESULTS: A total of 423 patients were evaluated. The TyG Index with a cut-off point of 8.76 excluded significant simple steatosis (grade 2-3) in obese patients, with 67.6% sensitivity, 65.1% specificity, 46.3% positive predictive value (PPV), 81.8% negative predictive value (NPV), 65.8% accuracy and 0.66 AUROC (P=0.005). In the evaluation of NASH, the TyG Index with a cut-off point of 8.82 excluded significant NASH (grade 2-3) with 57.3% sensitivity, 58.6% specificity, 33.7% PPV, 78.8% NPV, 58.2% accuracy and 0.58 AUROC (P=0.022). When evaluating liver fibrosis, the TyG Index with a cut-off point of 8.91 showed a sensitivity of 61.8%, a specificity of 62.5%, a PPV of 13.8 and a NPV of 94.4% for exclusion of advanced fibrosis (F3-4), with a 62.4% accuracy and 0.69 AUROC (P<0.001). When analyzing the performance of NFS in the diagnosis of advanced fibrosis, the cut-off point <-1.455 excluded advanced fibrosis with sensitivity of 59.4%, specificity of 51%, PPV of 11%, NPV of 92.4% and accuracy of 51.7%. However, the cut-off point of 0.676 to diagnose advanced fibrosis presented sensitivity of 21.9%, specificity of 83%, PPV of 11.7%, NPV of 91.2% and 77.3% accuracy. The AUROC was 0.54 (P=0.480). CONCLUSION: TyG Index did not perform well in the diagnosis of significant steatosis and NASH. However, it was able to exclude advanced fibrosis in obese patients who are candidates for bariatric surgery. RESUMO CONTEXTO: A doença hepática gordurosa não-alcoólica (DHGNA) é a doença hepática mais prevalente no mundo. Nos Estados Unidos, a DHGNA já é a segunda causa de transplante hepático. O espectro da doença abrange desde a esteatose simples, que apresenta curso benigno, até esteato-hepatite não-alcoólica (EHNA), que pode progredir para cirrose e suas complicações. O desenvolvimento de métodos não invasivos para o diagnóstico e estadiamento da EHNA e da fibrose hepática visa diminuir a necessidade de biópsia hepática, um procedimento invasivo e não raro associado a complicações. OBJETIVO: Analisar o desempenho do índice triglicerídeo-glicose (TyG Index) para o diagnóstico e estadiamento da DHGNA em pacientes obesos. MÉTODOS: Este é um estudo transversal retrospectivo. Foram analisados todos os prontuários de pacientes candidatos a cirurgia bariátrica em um hospital de referência do Sul do Brasil e calculado o TyG Index, um escore composto por dois exames laboratoriais (triglicerídeos e glicose de jejum), realizados previamente à cirurgia. O desempenho do TyG Index em relação aos achados anatomopatológicos hepáticos foi avaliado, e calculada a curva ROC para avaliação de esteatose simples, EHNA e fibrose hepática. O NAFLD Fibrosis Score (NFS) também foi avaliado. RESULTADOS: Foram avaliados 423 pacientes. O melhor ponto de corte do TyG Index para a exclusão de esteatose simples significativa (grau 2-3) foi de 8,76, com sensibilidade 67,6%, especificidade 65,1%, valor preditivo positivo (VPP) 46,3%, valor preditivo negativo (VPN) 81,8%, acurácia 65,8% e AUROC 0,66 (P=0,005). Na avaliação de EHNA significativa (grau 2-3), o melhor ponto de corte foi de 8,82 com sensibilidade 57,3%, especificidade 58,6%, VPP 33,7%, VPN 78,8%, acurácia 58,8% e AUROC 0,58 (P=0,022). Em relação à fibrose avançada (grau 3-4), o melhor ponto de corte do TyG Index foi de 8,91 com sensibilidade 61,8%, especificidade 62,5%, VPP 13,8%, VPN 94,4%, acurácia 62,4% e AUROC 0,69 (P<0,001). Ao analisarmos o desempenho do NFS no diagnóstico de fibrose avançada, o ponto de corte de <-1,455 excluiu fibrose avançada com sensibilidade 59,4%, especificidade 51%, VPP 11%, VPN 92,4% e acurácia 51,7%. Entretanto, o ponto de corte de 0,676 para fibrose avançada apresentou sensibilidade de 21,9%, especificidade 83%, VPP 11,7%, VPN 91,2% e acurácia 77,3%. A AUROC foi de 0,54 (P=0,480). CONCLUSÃO: O TyG Index não apresentou bom desempenho para o diagnóstico e estadiamento da esteatose simples e da EHNA. Entretanto, foi capaz de excluir fibrose avançada em pacientes obesos candidatos a cirurgia bariátrica.
AbstractList ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple steatosis, which has a benign course, to steatohepatitis, which may progress to cirrhosis and its complications. The rising of noninvasive methods for diagnosing and staging non-alcoholic steatohepatitis (NASH) and fibrosis decreases the need of liver biopsy, as well as the costs and the occurrence of complications related to it. OBJECTIVE: To analyze the performance of the triglyceride-glucose index to evaluate steatosis, NASH and liver fibrosis in obese patients with NAFLD. METHODS: This is a retrospective cross-sectional study. Every medical record of patients who were candidates for bariatric surgery at a leading hospital in Southern Brazil were analyzed. The triglyceride-glucose index (TyG Index), a method composed only of two simple laboratory tests (serum triglycerides and fasting glucose levels), was performed prior to surgery. The TyG Index performance regarding the anatomopathological findings was evaluated, and the AUROC curve was calculated to evaluate the best cut-off point for diagnosing steatosis, non-alcoholic steatohepatitis and liver fibrosis grade. Also, the NAFLD fibrosis Score (NFS) was evaluated. RESULTS: A total of 423 patients were evaluated. The TyG Index with a cut-off point of 8.76 excluded significant simple steatosis (grade 2-3) in obese patients, with 67.6% sensitivity, 65.1% specificity, 46.3% positive predictive value (PPV), 81.8% negative predictive value (NPV), 65.8% accuracy and 0.66 AUROC (P=0.005). In the evaluation of NASH, the TyG Index with a cut-off point of 8.82 excluded significant NASH (grade 2-3) with 57.3% sensitivity, 58.6% specificity, 33.7% PPV, 78.8% NPV, 58.2% accuracy and 0.58 AUROC (P=0.022). When evaluating liver fibrosis, the TyG Index with a cut-off point of 8.91 showed a sensitivity of 61.8%, a specificity of 62.5%, a PPV of 13.8 and a NPV of 94.4% for exclusion of advanced fibrosis (F3-4), with a 62.4% accuracy and 0.69 AUROC (P<0.001). When analyzing the performance of NFS in the diagnosis of advanced fibrosis, the cut-off point <-1.455 excluded advanced fibrosis with sensitivity of 59.4%, specificity of 51%, PPV of 11%, NPV of 92.4% and accuracy of 51.7%. However, the cut-off point of 0.676 to diagnose advanced fibrosis presented sensitivity of 21.9%, specificity of 83%, PPV of 11.7%, NPV of 91.2% and 77.3% accuracy. The AUROC was 0.54 (P=0.480). CONCLUSION: TyG Index did not perform well in the diagnosis of significant steatosis and NASH. However, it was able to exclude advanced fibrosis in obese patients who are candidates for bariatric surgery.
ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple steatosis, which has a benign course, to steatohepatitis, which may progress to cirrhosis and its complications. The rising of noninvasive methods for diagnosing and staging non-alcoholic steatohepatitis (NASH) and fibrosis decreases the need of liver biopsy, as well as the costs and the occurrence of complications related to it. OBJECTIVE: To analyze the performance of the triglyceride-glucose index to evaluate steatosis, NASH and liver fibrosis in obese patients with NAFLD. METHODS: This is a retrospective cross-sectional study. Every medical record of patients who were candidates for bariatric surgery at a leading hospital in Southern Brazil were analyzed. The triglyceride-glucose index (TyG Index), a method composed only of two simple laboratory tests (serum triglycerides and fasting glucose levels), was performed prior to surgery. The TyG Index performance regarding the anatomopathological findings was evaluated, and the AUROC curve was calculated to evaluate the best cut-off point for diagnosing steatosis, non-alcoholic steatohepatitis and liver fibrosis grade. Also, the NAFLD fibrosis Score (NFS) was evaluated. RESULTS: A total of 423 patients were evaluated. The TyG Index with a cut-off point of 8.76 excluded significant simple steatosis (grade 2-3) in obese patients, with 67.6% sensitivity, 65.1% specificity, 46.3% positive predictive value (PPV), 81.8% negative predictive value (NPV), 65.8% accuracy and 0.66 AUROC (P=0.005). In the evaluation of NASH, the TyG Index with a cut-off point of 8.82 excluded significant NASH (grade 2-3) with 57.3% sensitivity, 58.6% specificity, 33.7% PPV, 78.8% NPV, 58.2% accuracy and 0.58 AUROC (P=0.022). When evaluating liver fibrosis, the TyG Index with a cut-off point of 8.91 showed a sensitivity of 61.8%, a specificity of 62.5%, a PPV of 13.8 and a NPV of 94.4% for exclusion of advanced fibrosis (F3-4), with a 62.4% accuracy and 0.69 AUROC (P<0.001). When analyzing the performance of NFS in the diagnosis of advanced fibrosis, the cut-off point <-1.455 excluded advanced fibrosis with sensitivity of 59.4%, specificity of 51%, PPV of 11%, NPV of 92.4% and accuracy of 51.7%. However, the cut-off point of 0.676 to diagnose advanced fibrosis presented sensitivity of 21.9%, specificity of 83%, PPV of 11.7%, NPV of 91.2% and 77.3% accuracy. The AUROC was 0.54 (P=0.480). CONCLUSION: TyG Index did not perform well in the diagnosis of significant steatosis and NASH. However, it was able to exclude advanced fibrosis in obese patients who are candidates for bariatric surgery. RESUMO CONTEXTO: A doença hepática gordurosa não-alcoólica (DHGNA) é a doença hepática mais prevalente no mundo. Nos Estados Unidos, a DHGNA já é a segunda causa de transplante hepático. O espectro da doença abrange desde a esteatose simples, que apresenta curso benigno, até esteato-hepatite não-alcoólica (EHNA), que pode progredir para cirrose e suas complicações. O desenvolvimento de métodos não invasivos para o diagnóstico e estadiamento da EHNA e da fibrose hepática visa diminuir a necessidade de biópsia hepática, um procedimento invasivo e não raro associado a complicações. OBJETIVO: Analisar o desempenho do índice triglicerídeo-glicose (TyG Index) para o diagnóstico e estadiamento da DHGNA em pacientes obesos. MÉTODOS: Este é um estudo transversal retrospectivo. Foram analisados todos os prontuários de pacientes candidatos a cirurgia bariátrica em um hospital de referência do Sul do Brasil e calculado o TyG Index, um escore composto por dois exames laboratoriais (triglicerídeos e glicose de jejum), realizados previamente à cirurgia. O desempenho do TyG Index em relação aos achados anatomopatológicos hepáticos foi avaliado, e calculada a curva ROC para avaliação de esteatose simples, EHNA e fibrose hepática. O NAFLD Fibrosis Score (NFS) também foi avaliado. RESULTADOS: Foram avaliados 423 pacientes. O melhor ponto de corte do TyG Index para a exclusão de esteatose simples significativa (grau 2-3) foi de 8,76, com sensibilidade 67,6%, especificidade 65,1%, valor preditivo positivo (VPP) 46,3%, valor preditivo negativo (VPN) 81,8%, acurácia 65,8% e AUROC 0,66 (P=0,005). Na avaliação de EHNA significativa (grau 2-3), o melhor ponto de corte foi de 8,82 com sensibilidade 57,3%, especificidade 58,6%, VPP 33,7%, VPN 78,8%, acurácia 58,8% e AUROC 0,58 (P=0,022). Em relação à fibrose avançada (grau 3-4), o melhor ponto de corte do TyG Index foi de 8,91 com sensibilidade 61,8%, especificidade 62,5%, VPP 13,8%, VPN 94,4%, acurácia 62,4% e AUROC 0,69 (P<0,001). Ao analisarmos o desempenho do NFS no diagnóstico de fibrose avançada, o ponto de corte de <-1,455 excluiu fibrose avançada com sensibilidade 59,4%, especificidade 51%, VPP 11%, VPN 92,4% e acurácia 51,7%. Entretanto, o ponto de corte de 0,676 para fibrose avançada apresentou sensibilidade de 21,9%, especificidade 83%, VPP 11,7%, VPN 91,2% e acurácia 77,3%. A AUROC foi de 0,54 (P=0,480). CONCLUSÃO: O TyG Index não apresentou bom desempenho para o diagnóstico e estadiamento da esteatose simples e da EHNA. Entretanto, foi capaz de excluir fibrose avançada em pacientes obesos candidatos a cirurgia bariátrica.
BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple steatosis, which has a benign course, to steatohepatitis, which may progress to cirrhosis and its complications. The rising of noninvasive methods for diagnosing and staging non-alcoholic steatohepatitis (NASH) and fibrosis decreases the need of liver biopsy, as well as the costs and the occurrence of complications related to it. OBJECTIVETo analyze the performance of the triglyceride-glucose index to evaluate steatosis, NASH and liver fibrosis in obese patients with NAFLD. METHODSThis is a retrospective cross-sectional study. Every medical record of patients who were candidates for bariatric surgery at a leading hospital in Southern Brazil were analyzed. The triglyceride-glucose index (TyG Index), a method composed only of two simple laboratory tests (serum triglycerides and fasting glucose levels), was performed prior to surgery. The TyG Index performance regarding the anatomopathological findings was evaluated, and the AUROC curve was calculated to evaluate the best cut-off point for diagnosing steatosis, non-alcoholic steatohepatitis and liver fibrosis grade. Also, the NAFLD fibrosis Score (NFS) was evaluated. RESULTSA total of 423 patients were evaluated. The TyG Index with a cut-off point of 8.76 excluded significant simple steatosis (grade 2-3) in obese patients, with 67.6% sensitivity, 65.1% specificity, 46.3% positive predictive value (PPV), 81.8% negative predictive value (NPV), 65.8% accuracy and 0.66 AUROC (P=0.005). In the evaluation of NASH, the TyG Index with a cut-off point of 8.82 excluded significant NASH (grade 2-3) with 57.3% sensitivity, 58.6% specificity, 33.7% PPV, 78.8% NPV, 58.2% accuracy and 0.58 AUROC (P=0.022). When evaluating liver fibrosis, the TyG Index with a cut-off point of 8.91 showed a sensitivity of 61.8%, a specificity of 62.5%, a PPV of 13.8 and a NPV of 94.4% for exclusion of advanced fibrosis (F3-4), with a 62.4% accuracy and 0.69 AUROC (P<0.001). When analyzing the performance of NFS in the diagnosis of advanced fibrosis, the cut-off point <-1.455 excluded advanced fibrosis with sensitivity of 59.4%, specificity of 51%, PPV of 11%, NPV of 92.4% and accuracy of 51.7%. However, the cut-off point of 0.676 to diagnose advanced fibrosis presented sensitivity of 21.9%, specificity of 83%, PPV of 11.7%, NPV of 91.2% and 77.3% accuracy. The AUROC was 0.54 (P=0.480). CONCLUSIONTyG Index did not perform well in the diagnosis of significant steatosis and NASH. However, it was able to exclude advanced fibrosis in obese patients who are candidates for bariatric surgery.
Author MATTOS, Angelo Zambam de
DE CARLI, Luiz Alberto
MATTOS, Angelo Alves de
TOVO, Cristiane Valle
CORAL, Gabriela Perdomo
SMIDERLE, Carla Alessandra
AuthorAffiliation Santa Casa de Misericórdia de Porto Alegre
Universidade Federal de Ciências da Saúde de Porto Alegre
AuthorAffiliation_xml – name: Universidade Federal de Ciências da Saúde de Porto Alegre
– name: Santa Casa de Misericórdia de Porto Alegre
Author_xml – sequence: 1
  givenname: Carla Alessandra
  orcidid: 0000-0002-2873-7069
  surname: SMIDERLE
  fullname: SMIDERLE, Carla Alessandra
  organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil
– sequence: 2
  givenname: Gabriela Perdomo
  orcidid: 0000-0003-4318-2871
  surname: CORAL
  fullname: CORAL, Gabriela Perdomo
  organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil; Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil
– sequence: 3
  givenname: Luiz Alberto
  orcidid: 0000-0001-8875-9908
  surname: DE CARLI
  fullname: DE CARLI, Luiz Alberto
  organization: Santa Casa de Misericórdia de Porto Alegre, Brasil
– sequence: 4
  givenname: Angelo Alves de
  orcidid: 0000-0003-2417-9765
  surname: MATTOS
  fullname: MATTOS, Angelo Alves de
  organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil; Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil
– sequence: 5
  givenname: Angelo Zambam de
  orcidid: 0000-0002-3063-0199
  surname: MATTOS
  fullname: MATTOS, Angelo Zambam de
  organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil; Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil
– sequence: 6
  givenname: Cristiane Valle
  orcidid: 0000-0002-7932-5937
  surname: TOVO
  fullname: TOVO, Cristiane Valle
  organization: Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil; Universidade Federal de Ciências da Saúde de Porto Alegre, Brasil
BookMark eNo9UU1r3DAQFSWFbpL-hvrYizf68oeOrq11BY4d1g60UBCSVipenFVqZQ_997W7YWcOAzPvvRne3IKbkz9ZAL4guEUJgw8BQkhjnEOyxRAjuEaM6QewQWmWxxQjdgM2V9AncBvCEUJMGUs34NcT3--6_WNR8qjbRcNe1M3Pku9FxeO6eS67nkeirfiPqGujShR12_Wij4q2ivqhqEVbr7S22DXVgou6b3whPBWD4O3Q34OPTk3Bfn6vd-B5x4fye9x0tSiLJjYkYTRmNksh1SrVGULMOERcjlhClU5IYjXT2DrklDmQZW5RliPMqIEMWUcOOtfkDoiL7sGro3ydxxc1_5VejfJ_w8-_pZrfRjNZmTqUJc5BumaONMsVIxoZ6OzB5owuWtuLVjCjnbw8-vN8Wo6X_WqhXC18txlDiAhbCF8vhNfZ_znb8CZfxmDsNKmT9ecgcUIZhoTSVTu7QM3sQ5itu96KoFyfKcN1ibw-U2JK_gGwnYdx
CitedBy_id crossref_primary_10_3390_molecules28155645
crossref_primary_10_3390_nu14234969
crossref_primary_10_1186_s12876_024_03164_4
crossref_primary_10_3389_fendo_2022_1043169
crossref_primary_10_1186_s12933_022_01548_y
crossref_primary_10_1080_00365521_2024_2305268
crossref_primary_10_3390_jpm13050830
Cites_doi 10.1007/s00535-015-1114-8
10.1016/j.soard.2014.06.015
10.1186/s12944-017-0409-6
10.1007/s11695-017-2829-9
10.1002/hep.20701
10.1002/hep.28431
10.1016/j.aohep.2018.09.003
10.1186/s12944-018-0913-3
10.1111/apt.12963
10.1097/MEG.0000000000001519
10.1002/hep.21496
10.1016/j.soard.2019.01.035
10.1016/j.cgh.2009.05.033
10.1016/j.soard.2015.11.011
10.1002/hep.29367
10.1016/j.jhep.2019.06.021
10.3390/ijms161025552
10.1053/j.gastro.2014.11.039
10.1089/met.2008.0034
10.1001/archsurg.138.11.1240
10.1053/j.gastro.2010.09.038
10.1016/S0168-8278(18)31946-9
10.1038/s41395-018-0088-6
ContentType Journal Article
Copyright This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright_xml – notice: This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DBID AAYXX
CITATION
7X8
GPN
DOA
DOI 10.1590/s0004-2803.202100000-24
DatabaseName CrossRef
MEDLINE - Academic
SciELO
Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Avaliação do desempenho do índice triglicerídeo-glicose no diagnóstico e estadiamento da DHGNA em pacientes obesos
EISSN 1678-4219
EndPage 144
ExternalDocumentID oai_doaj_org_article_6f175ff04040481b98a93b1c0fede894
S0004_28032021000200139
10_1590_s0004_2803_202100000_24
GroupedDBID 23N
2WC
53G
5GY
5VS
6J9
AAYXX
ABXHO
ADBBV
ALMA_UNASSIGNED_HOLDINGS
APOWU
AZFZN
BAWUL
BCNDV
C1A
CITATION
CS3
DIK
E3Z
EBS
EJD
F5P
GROUPED_DOAJ
GX1
IPNFZ
KQ8
M~E
OK1
P2P
RIG
RNS
RSC
SCD
XSB
ZXP
7X8
GPN
ID FETCH-LOGICAL-c3594-9e7604ba6b7119cf13f81954ab535eb9b2ef1facd3711e1781294c091ef3db8b3
IEDL.DBID DOA
ISSN 0004-2803
1678-4219
IngestDate Tue Oct 22 15:06:53 EDT 2024
Tue Nov 19 21:47:51 EST 2024
Fri Jun 28 12:02:29 EDT 2024
Fri Aug 23 03:21:44 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords nonalcoholic steatohepatitis
hepatopatia gordurosa não-alcoólica
cirurgia bariátrica
Obesity
nonalcoholic fatty liver disease
NAFLD
esteatose hepática
bariatric surgery
fatty liver
Obesidade
esteato-hepatite
Language English
License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. http://creativecommons.org/licenses/by-nc/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3594-9e7604ba6b7119cf13f81954ab535eb9b2ef1facd3711e1781294c091ef3db8b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-4318-2871
0000-0001-8875-9908
0000-0002-7932-5937
0000-0002-2873-7069
0000-0003-2417-9765
0000-0002-3063-0199
OpenAccessLink https://doaj.org/article/6f175ff04040481b98a93b1c0fede894
PQID 2549203444
PQPubID 23479
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_6f175ff04040481b98a93b1c0fede894
scielo_journals_S0004_28032021000200139
proquest_miscellaneous_2549203444
crossref_primary_10_1590_s0004_2803_202100000_24
PublicationCentury 2000
PublicationDate 20210601
PublicationDateYYYYMMDD 2021-06-01
PublicationDate_xml – month: 06
  year: 2021
  text: 20210601
  day: 01
PublicationDecade 2020
PublicationTitle Arquivos de gastroenterologia
PublicationTitleAlternate Arq. Gastroenterol
PublicationYear 2021
Publisher Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)
Publisher_xml – name: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE
– name: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)
References Simental-Mendía LE (ref16) 2008; 6
Tovo C V. (ref25) 2019; 18
Faure S (ref14) 2018; 68
Younossi ZM (ref4) 2019; 71
Al de Carli M (ref24) 2020; 32
Angulo P (ref11) 2007; 45
Wong RJ (ref7) 2015; 148
Seki Y (ref19) 2016; 51
Losekann A (ref6) 2015; 16
Simental-Mendía LE (ref13) 2016; 15
Shah AG (ref12) 2009; 7
Haflidadottir S (ref8) 2014; 27
Younossi ZM (ref1) 2016; 64
De Cleva R (ref26) 2016; 12
Subichin M (ref2) 2015; 11
Williams CD (ref5) 2011; 140
Fedchuk L (ref22) 2014; 40
Kruger FC (ref10) 2011; 101
Noureddin M (ref9) 2018; 113
Cazzo E (ref23) 2018; 28
Kleiner DE (ref15) 2005; 41
Udelsman B V. (ref18) 2019; 15
Zheng R (ref20) 2018; 17
Chalasani N (ref3) 2018; 67
Beymer C (ref17) 2003; 138
Zhang S (ref21) 2017; 16
Younossi, ZM; Koenig, AB; Abdelatif, D; Fazel, Y; Henry, L; Wymer, M 2016; 64
Beymer, C; Kowdley K, V; Larson, A; Edmonson, P; Dellinger, EP; Flum, DR 2003; 138
Zhang, S; Du, T; Zhang, J; Lu, H; Lin, X; Xie, J 2017; 16
Simental-Mendía, LE; Simental-Mendía, E; Rodríguez-Hernández, H; Rodríguez-Morán, M; Guerrero-Romero, F 2016; 15
Angulo, P; Hui, JM; Marchesini, G; Bugianesi, E; George, J; Farrell, GC 2007; 45
Fedchuk, L; Nascimbeni, F; Pais, R; Charlotte, F; Housset, C; Ratziu, V 2014; 40
Seki, Y; Kakizaki, S; Horiguchi, N; Hashizume, H; Tojima, H; Yamazaki, Y 2016; 51
Subichin, M; Clanton, J; Makuszewski, M; Bohon, A; Zografakis, JG; Dan, A 2015; 11
Wong, RJ; Aguilar, M; Cheung, R; Perumpail, RB; Harrison, SA; Younossi, ZM 2015; 148
Shah, AG; Lydecker, A; Murray, K; Tetri, BN; Contos, MJ; Sanyal, AJ 2009; 7
Faure, S; Benjamin, R; Ramos, J; Medhi, S; David, N; Anne, L 2018; 68
Al, de Carli M; de Carli, LA; Correa, MB; Junqueira, G; Tovo, CV; Coral, GP 2020; 32
Simental-Mendía, LE; Rodríguez-Morán, M; Guerrero-Romero, F 2008; 6
Losekann, A; Weston, A; de Mattos, A; Tovo, C; de Carli, L; Espindola, M 2015; 16
Noureddin, M; Vipani, A; Bresee, C; Todo, T; Kim, IK; Alkhouri, N 2018; 113
De Cleva, R; Duarte, LF; Crenitte, MRF; De Oliveira, CPM; Pajecki, D; Santo, MA 2016; 12
Younossi, ZM; Golabi, P; de Avila, L; Paik, JM; Srishord, M; Fukui, N 2019; 71
Chalasani, N; Younossi, Z; Lavine, JE; Charlton, M; Cusi, K; Rinella, M 2018; 67
Kruger, FC; Daniels, CR; Kidd, M; Swart, G; Brundyn, K; van Rensburg, C 2011; 101
Haflidadottir, S; Jonasson, JG; Norland, H; Einarsdottir, SO; Kleiner, DE; Lund, SH 2014; 27
Williams, CD; Stengel, J; Asike, MI; Torres, DM; Shaw, J; Contreras, M 2011; 140
Udelsman B, V.; Corey, KE; Lindvall, C; Gee, DW; Meireles, OR; Hutter, MM 2019; 15
Zheng, R; Du, Z; Wang, M; Mao, Y; Mao, W 2018; 17
Kleiner, DE; Brunt, EM; Van Natta, M; Behling, C; Contos, MJ; Cummings, OW 2005; 41
Cazzo, E; Jimenez, LS; Gestic, MA; Utrini, MP; Chaim, FHM; Chaim, FDM 2018; 28
Tovo C, V.; Villela-Nogueira, CA; Leite, NC; Panke, CL; Port, GZ; Fernandes, S 2019; 18
References_xml – volume: 51
  start-page: 281
  year: 2016
  ident: ref19
  article-title: Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-015-1114-8
  contributor:
    fullname: Seki Y
– volume: 11
  start-page: 137
  year: 2015
  ident: ref2
  article-title: Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery
  publication-title: Surg Obes Relat Dis
  doi: 10.1016/j.soard.2014.06.015
  contributor:
    fullname: Subichin M
– volume: 16
  start-page: 15
  year: 2017
  ident: ref21
  article-title: The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease
  publication-title: Lipids Health Dis
  doi: 10.1186/s12944-017-0409-6
  contributor:
    fullname: Zhang S
– volume: 28
  start-page: 187
  year: 2018
  ident: ref23
  article-title: Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features
  publication-title: Obes Surg
  doi: 10.1007/s11695-017-2829-9
  contributor:
    fullname: Cazzo E
– volume: 41
  start-page: 1313
  year: 2005
  ident: ref15
  article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease
  publication-title: Hepatology
  doi: 10.1002/hep.20701
  contributor:
    fullname: Kleiner DE
– volume: 101
  start-page: 477
  year: 2011
  ident: ref10
  article-title: APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH
  publication-title: S Afr Med J
  contributor:
    fullname: Kruger FC
– volume: 64
  start-page: 73
  year: 2016
  ident: ref1
  article-title: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
  publication-title: Hepatology
  doi: 10.1002/hep.28431
  contributor:
    fullname: Younossi ZM
– volume: 18
  start-page: 445
  year: 2019
  ident: ref25
  article-title: Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD)
  publication-title: Ann Hepatol
  doi: 10.1016/j.aohep.2018.09.003
  contributor:
    fullname: Tovo C V.
– volume: 17
  start-page: 262
  year: 2018
  ident: ref20
  article-title: A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease
  publication-title: Lipids Health Dis
  doi: 10.1186/s12944-018-0913-3
  contributor:
    fullname: Zheng R
– volume: 40
  start-page: 1209
  year: 2014
  ident: ref22
  article-title: Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.12963
  contributor:
    fullname: Fedchuk L
– volume: 32
  start-page: 420
  year: 2020
  ident: ref24
  article-title: Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0000000000001519
  contributor:
    fullname: Al de Carli M
– volume: 45
  start-page: 846
  year: 2007
  ident: ref11
  article-title: The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
  publication-title: Hepatology
  doi: 10.1002/hep.21496
  contributor:
    fullname: Angulo P
– volume: 15
  start-page: 843
  year: 2019
  ident: ref18
  article-title: Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery
  publication-title: Surg Obes Relat Dis
  doi: 10.1016/j.soard.2019.01.035
  contributor:
    fullname: Udelsman B V.
– volume: 7
  start-page: 1104
  year: 2009
  ident: ref12
  article-title: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2009.05.033
  contributor:
    fullname: Shah AG
– volume: 12
  start-page: 862
  year: 2016
  ident: ref26
  article-title: Use of noninvasive markers to predict advanced fibrosis/cirrhosis in severe obesity
  publication-title: Surg Obes Relat Dis
  doi: 10.1016/j.soard.2015.11.011
  contributor:
    fullname: De Cleva R
– volume: 67
  start-page: 328
  year: 2018
  ident: ref3
  article-title: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
  publication-title: Hepatology
  doi: 10.1002/hep.29367
  contributor:
    fullname: Chalasani N
– volume: 71
  start-page: 793
  year: 2019
  ident: ref4
  article-title: The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2019.06.021
  contributor:
    fullname: Younossi ZM
– volume: 16
  start-page: 25552
  year: 2015
  ident: ref6
  article-title: Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms161025552
  contributor:
    fullname: Losekann A
– volume: 148
  start-page: 547
  year: 2015
  ident: ref7
  article-title: Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2014.11.039
  contributor:
    fullname: Wong RJ
– volume: 15
  start-page: 715
  year: 2016
  ident: ref13
  article-title: The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women
  publication-title: Ann Hepatol
  contributor:
    fullname: Simental-Mendía LE
– volume: 6
  start-page: 299
  year: 2008
  ident: ref16
  article-title: The Product of Fasting Glucose and Triglycerides As Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects
  publication-title: Metab Syndr Relat Disord
  doi: 10.1089/met.2008.0034
  contributor:
    fullname: Simental-Mendía LE
– volume: 138
  start-page: 1240
  year: 2003
  ident: ref17
  article-title: Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery
  publication-title: Arch Surg
  doi: 10.1001/archsurg.138.11.1240
  contributor:
    fullname: Beymer C
– volume: 140
  start-page: 124
  year: 2011
  ident: ref5
  article-title: Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2010.09.038
  contributor:
    fullname: Williams CD
– volume: 68
  start-page: S835
  year: 2018
  ident: ref14
  article-title: The triglycerides and glucose (TyG) index: a new marker associated with Non Alcoholic Steatohepatitis (NASH) and fibrosis in obese patients?
  publication-title: J Hepatol
  doi: 10.1016/S0168-8278(18)31946-9
  contributor:
    fullname: Faure S
– volume: 113
  start-page: 1649
  year: 2018
  ident: ref9
  article-title: NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender Variances
  publication-title: Am J Gastroenterol
  doi: 10.1038/s41395-018-0088-6
  contributor:
    fullname: Noureddin M
– volume: 27
  start-page: 14
  year: 2014
  ident: ref8
  article-title: Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease
  publication-title: BMC Gastroenterol
  contributor:
    fullname: Haflidadottir S
– volume: 41
  start-page: 1313
  year: 2005
  end-page: 1321
  article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease
  publication-title: Hepatology
  contributor:
    fullname: Kleiner, DE; Brunt, EM; Van Natta, M; Behling, C; Contos, MJ; Cummings, OW
– volume: 12
  start-page: 862
  year: 2016
  end-page: 867
  article-title: Use of noninvasive markers to predict advanced fibrosis/cirrhosis in severe obesity
  publication-title: Surg Obes Relat Dis
  contributor:
    fullname: De Cleva, R; Duarte, LF; Crenitte, MRF; De Oliveira, CPM; Pajecki, D; Santo, MA
– volume: 17
  start-page: 262
  year: 2018
  end-page: 262
  article-title: A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease
  publication-title: Lipids Health Dis
  contributor:
    fullname: Zheng, R; Du, Z; Wang, M; Mao, Y; Mao, W
– volume: 16
  start-page: 25552
  year: 2015
  end-page: 25559
  article-title: Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
  publication-title: Int J Mol Sci
  contributor:
    fullname: Losekann, A; Weston, A; de Mattos, A; Tovo, C; de Carli, L; Espindola, M
– volume: 45
  start-page: 846
  year: 2007
  end-page: 854
  article-title: The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
  publication-title: Hepatology
  contributor:
    fullname: Angulo, P; Hui, JM; Marchesini, G; Bugianesi, E; George, J; Farrell, GC
– volume: 32
  start-page: 420
  year: 2020
  end-page: 425
  article-title: Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease
  publication-title: Eur J Gastroenterol Hepatol
  contributor:
    fullname: Al, de Carli M; de Carli, LA; Correa, MB; Junqueira, G; Tovo, CV; Coral, GP
– volume: 113
  start-page: 1649
  year: 2018
  end-page: 1659
  article-title: NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender Variances
  publication-title: Am J Gastroenterol
  contributor:
    fullname: Noureddin, M; Vipani, A; Bresee, C; Todo, T; Kim, IK; Alkhouri, N
– volume: 28
  start-page: 187
  year: 2018
  end-page: 194
  article-title: Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features
  publication-title: Obes Surg
  contributor:
    fullname: Cazzo, E; Jimenez, LS; Gestic, MA; Utrini, MP; Chaim, FHM; Chaim, FDM
– volume: 140
  start-page: 124
  year: 2011
  end-page: 131
  article-title: Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
  publication-title: Gastroenterology
  contributor:
    fullname: Williams, CD; Stengel, J; Asike, MI; Torres, DM; Shaw, J; Contreras, M
– volume: 64
  start-page: 73
  year: 2016
  end-page: 84
  article-title: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
  publication-title: Hepatology
  contributor:
    fullname: Younossi, ZM; Koenig, AB; Abdelatif, D; Fazel, Y; Henry, L; Wymer, M
– volume: 18
  start-page: 445
  year: 2019
  end-page: 449
  article-title: Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD)
  publication-title: Ann Hepatol
  contributor:
    fullname: Tovo C, V.; Villela-Nogueira, CA; Leite, NC; Panke, CL; Port, GZ; Fernandes, S
– volume: 15
  start-page: 843
  year: 2019
  end-page: 849
  article-title: Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery
  publication-title: Surg Obes Relat Dis
  contributor:
    fullname: Udelsman B, V.; Corey, KE; Lindvall, C; Gee, DW; Meireles, OR; Hutter, MM
– volume: 6
  start-page: 299
  year: 2008
  end-page: 304
  article-title: The Product of Fasting Glucose and Triglycerides As Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects
  publication-title: Metab Syndr Relat Disord
  contributor:
    fullname: Simental-Mendía, LE; Rodríguez-Morán, M; Guerrero-Romero, F
– volume: 40
  start-page: 1209
  year: 2014
  end-page: 1222
  article-title: Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
  publication-title: Aliment Pharmacol Ther
  contributor:
    fullname: Fedchuk, L; Nascimbeni, F; Pais, R; Charlotte, F; Housset, C; Ratziu, V
– volume: 7
  start-page: 1104
  year: 2009
  end-page: 1112
  article-title: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease
  publication-title: Clin Gastroenterol Hepatol
  contributor:
    fullname: Shah, AG; Lydecker, A; Murray, K; Tetri, BN; Contos, MJ; Sanyal, AJ
– volume: 11
  start-page: 137
  year: 2015
  end-page: 141
  article-title: Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery
  publication-title: Surg Obes Relat Dis
  contributor:
    fullname: Subichin, M; Clanton, J; Makuszewski, M; Bohon, A; Zografakis, JG; Dan, A
– volume: 67
  start-page: 328
  year: 2018
  end-page: 357
  article-title: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
  publication-title: Hepatology
  contributor:
    fullname: Chalasani, N; Younossi, Z; Lavine, JE; Charlton, M; Cusi, K; Rinella, M
– volume: 27
  start-page: 14
  year: 2014
  end-page: 166
  article-title: Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease
  publication-title: BMC Gastroenterol
  contributor:
    fullname: Haflidadottir, S; Jonasson, JG; Norland, H; Einarsdottir, SO; Kleiner, DE; Lund, SH
– volume: 51
  start-page: 281
  year: 2016
  end-page: 289
  article-title: Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery
  publication-title: J Gastroenterol
  contributor:
    fullname: Seki, Y; Kakizaki, S; Horiguchi, N; Hashizume, H; Tojima, H; Yamazaki, Y
– volume: 68
  start-page: S835
  year: 2018
  end-page: S835
  article-title: The triglycerides and glucose (TyG) index: a new marker associated with Non Alcoholic Steatohepatitis (NASH) and fibrosis in obese patients?
  publication-title: J Hepatol
  contributor:
    fullname: Faure, S; Benjamin, R; Ramos, J; Medhi, S; David, N; Anne, L
– volume: 71
  start-page: 793
  year: 2019
  end-page: 801
  article-title: The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
  publication-title: J Hepatol
  contributor:
    fullname: Younossi, ZM; Golabi, P; de Avila, L; Paik, JM; Srishord, M; Fukui, N
– volume: 148
  start-page: 547
  year: 2015
  end-page: 555
  article-title: Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
  publication-title: Gastroenterology
  contributor:
    fullname: Wong, RJ; Aguilar, M; Cheung, R; Perumpail, RB; Harrison, SA; Younossi, ZM
– volume: 16
  start-page: 15
  year: 2017
  end-page: 15
  article-title: The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease
  publication-title: Lipids Health Dis
  contributor:
    fullname: Zhang, S; Du, T; Zhang, J; Lu, H; Lin, X; Xie, J
– volume: 101
  start-page: 477
  year: 2011
  end-page: 480
  article-title: APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH
  publication-title: S Afr Med J
  contributor:
    fullname: Kruger, FC; Daniels, CR; Kidd, M; Swart, G; Brundyn, K; van Rensburg, C
– volume: 15
  start-page: 715
  year: 2016
  end-page: 720
  article-title: The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women
  publication-title: Ann Hepatol
  contributor:
    fullname: Simental-Mendía, LE; Simental-Mendía, E; Rodríguez-Hernández, H; Rodríguez-Morán, M; Guerrero-Romero, F
– volume: 138
  start-page: 1240
  year: 2003
  end-page: 1244
  article-title: Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery
  publication-title: Arch Surg
  contributor:
    fullname: Beymer, C; Kowdley K, V; Larson, A; Edmonson, P; Dellinger, EP; Flum, DR
SSID ssj0024996
Score 2.2914486
Snippet ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside...
BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In...
SourceID doaj
scielo
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 139
SubjectTerms bariatric surgery
fatty liver
GASTROENTEROLOGY & HEPATOLOGY
NAFLD
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
Obesity
Title PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS
URI https://search.proquest.com/docview/2549203444
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032021000200139&lng=en&tlng=en
https://doaj.org/article/6f175ff04040481b98a93b1c0fede894
Volume 58
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwFLQoB8SloqUVS1tkJKSeojqx8-Fj2HhDxJIgEiSQkKz464QW1GX_f5-T7Kqceuk1sa2nebbmjW2NEbqgPWWx1jFUbhoESq-yQAENBWGmQqO4icyw4XbVpvVDVghvk7N76svfCRvtgUfgfiUOCM45mGvMW5sonvWcqlATZ43N-OgESpKtmNq67EEZP93mijnxlqGEBf4hJlCE0bClTYKIveOiwbL_fZ3pSej5b75ZHKGPU6GI8zHAT2jPrj6jg5vpKPwYPd2KO1BwN_lc4GaBu7uqXD7OQZYVIiiX9_OmFbiqC_GAmxoXVV7WTVu1OK8L3HZ5WdWl71bni2UB7XBzKaDDbd5Vou7aL-h-Ibr5VTA9lRBoGnMWcJsmhKk-UWkYcu1C6vwBGWAf09gqriLrQtdrQ-G_DVOgdc401ArWUaMyRb-i_dXLyp4grIH0tSIJoZlmfW9A8qTeJjCBvlZzM0NkC5p8HR0xpFcSgLMccJYeZ7nDWUZshi49uLvm3tJ6-ACJllOi5b8SPUPn29RIWAL-XKNf2ZfNWnqNG3nrQmjzc8yZnFbiWra7kKaIoqHqPf0fIX1Dh37Q8ebYd7T_9ntjf6APa7M5g-lYXZ8Nk_IPQK3VkA
link.rule.ids 230,315,782,786,866,887,2106,27933,27934
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PERFORMACE+OF+TRIGLYCERIDE-GLUCOSE+INDEX+ON+DIAGNOSIS+AND+STAGING+OF+NAFLD+IN+OBESE+PATIENTS&rft.jtitle=Arquivos+de+gastroenterologia&rft.au=Smiderle%2C+Carla+Alessandra&rft.au=Coral%2C+Gabriela+Perdomo&rft.au=DE+Carli%2C+Luiz+Alberto&rft.au=Mattos%2C+Angelo+Alves+de&rft.date=2021-06-01&rft.eissn=1678-4219&rft.volume=58&rft.issue=2&rft.spage=139&rft.epage=144&rft_id=info:doi/10.1590%2FS0004-2803.202100000-24&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0004-2803&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0004-2803&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0004-2803&client=summon